These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

378 related items for PubMed ID: 19667676

  • 1. Redefining insulin therapy in type 2 diabetes mellitus.
    Rosenstock J.
    Postgrad Med; 2004 Nov; 116(5 Suppl Exploring):21-9. PubMed ID: 19667676
    [Abstract] [Full Text] [Related]

  • 2. Combination therapy with insulin and oral agents: optimizing glycemic control in patients with type 2 diabetes mellitus.
    Yki-Järvinen H.
    Diabetes Metab Res Rev; 2002 Nov; 18 Suppl 3():S77-81. PubMed ID: 12324990
    [Abstract] [Full Text] [Related]

  • 3. Effective switch from premixed to basal-prandial insulin to achieve glycemic goals in type 2 diabetes.
    Lavernia F.
    Postgrad Med; 2010 May; 122(3):28-32. PubMed ID: 20463411
    [Abstract] [Full Text] [Related]

  • 4. Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 diabetes patients: the PREDICTIVE BMI clinical trial.
    Fajardo Montañana C, Hernández Herrero C, Rivas Fernández M.
    Diabet Med; 2008 Aug; 25(8):916-23. PubMed ID: 18959604
    [Abstract] [Full Text] [Related]

  • 5. Treatment of type 2 diabetes with combined therapy: what are the pros and cons?
    Massi-Benedetti M, Orsini-Federici M.
    Diabetes Care; 2008 Feb; 31 Suppl 2():S131-5. PubMed ID: 18227473
    [Abstract] [Full Text] [Related]

  • 6. [Costs of antihyperglycemic drugs and consumables and treatment satisfaction in patients with type 2 diabetes. Results of the health care research study LIVE-DE (long-acting insulin glargine compared with NPH insulin in Germany)].
    Hauner H, Kohlmann T, Landgraf W, Holle R, Pirk O, Scholten T.
    Dtsch Med Wochenschr; 2009 Jun; 134(23):1207-13. PubMed ID: 19472091
    [Abstract] [Full Text] [Related]

  • 7. Type 1 diabetes mellitus: effective insulin strategies with less hypoglycemia.
    Bolli GB.
    Postgrad Med; 2004 Nov; 116(5 Suppl Exploring):13-20. PubMed ID: 19667675
    [Abstract] [Full Text] [Related]

  • 8. Basal plus basal-bolus approach in type 2 diabetes.
    Ampudia-Blasco FJ, Rossetti P, Ascaso JF.
    Diabetes Technol Ther; 2011 Jun; 13 Suppl 1():S75-83. PubMed ID: 21668340
    [Abstract] [Full Text] [Related]

  • 9. Oral combination therapy: repaglinide plus metformin for treatment of type 2 diabetes.
    Raskin P.
    Diabetes Obes Metab; 2008 Dec; 10(12):1167-77. PubMed ID: 18494804
    [Abstract] [Full Text] [Related]

  • 10. Initiating insulin in patients with type 2 diabetes.
    Aoki TJ, White RD.
    J Fam Pract; 2007 Aug; 56(8 Suppl Hot Topics):S12-20. PubMed ID: 18667139
    [Abstract] [Full Text] [Related]

  • 11. Fine-tuning therapy with basal insulin for optimal glycemic control in type 2 diabetes: a review.
    Dailey G.
    Curr Med Res Opin; 2004 Dec; 20(12):2007-14. PubMed ID: 15701217
    [Abstract] [Full Text] [Related]

  • 12. The development of an oral antidiabetic combination tablet: design, evaluation and clinical benefits for patients with type 2 diabetes.
    Howlett H, Porte F, Allavoine T, Kuhn T, Nicholson G.
    Curr Med Res Opin; 2003 Dec; 19(3):218-25. PubMed ID: 12803736
    [Abstract] [Full Text] [Related]

  • 13. Comparison of glycaemic control in patients with Type 2 diabetes on basal insulin and fixed combination oral antidiabetic treatment: results of a pilot study.
    De Mattia G, Laurenti O, Moretti A.
    Acta Diabetol; 2009 Mar; 46(1):67-73. PubMed ID: 19030772
    [Abstract] [Full Text] [Related]

  • 14. The role of new basal insulin analogues in the initiation and optimisation of insulin therapy in type 2 diabetes.
    Baxter MA.
    Acta Diabetol; 2008 Dec; 45(4):253-68. PubMed ID: 18766296
    [Abstract] [Full Text] [Related]

  • 15. Why, when and how to initiate insulin therapy in patients with type 2 diabetes.
    Tibaldi J, Rakel RE.
    Int J Clin Pract; 2007 Apr; 61(4):633-44. PubMed ID: 17394436
    [Abstract] [Full Text] [Related]

  • 16. Economic evaluation of the treatment of type 2 diabetes with insulin glargine based on the LAPTOP trial.
    Janka HU, Högy B.
    Eur J Health Econ; 2008 May; 9(2):165-70. PubMed ID: 17530309
    [Abstract] [Full Text] [Related]

  • 17. Why insulin sensitizers but not secretagogues should be retained when initiating insulin in type 2 diabetes.
    Raskin P.
    Diabetes Metab Res Rev; 2008 May; 24(1):3-13. PubMed ID: 17968971
    [Abstract] [Full Text] [Related]

  • 18. When oral agents fail: optimizing insulin therapy in the older adult.
    Meece J.
    Consult Pharm; 2009 Jun; 24 Suppl B():11-7. PubMed ID: 19555131
    [Abstract] [Full Text] [Related]

  • 19. Making the transition from oral to insulin therapy.
    Riddle MC.
    Am J Med; 2005 May; 118 Suppl 5A():14S-20S. PubMed ID: 15850549
    [Abstract] [Full Text] [Related]

  • 20. Insulins and oral hypoglycemic agents in pregnancy.
    Homko CJ, Reece EA.
    J Matern Fetal Neonatal Med; 2006 Nov; 19(11):679-86. PubMed ID: 17127490
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.